Post|Hoc Analysis Demonstrating Sotagliflozin Benefits Across ...

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across ...

Researchers in the study observed that sotagliflozin had similar relative benefits for all endpoints, irrespective of heart failure stage, with ...

Lexicon's Sotagliflozin Shows Strong Benefits Across All Heart ...

A key secondary analysis of the Phase 3 SCORED trial showed sotagliflozin provided similar relative benefits across all heart failure stages, ...

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across ...

Researchers in the study observed that sotagliflozin had similar relative benefits for all endpoints, irrespective of heart failure stage, with ...

Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin ...

Over 0–14 h, both sotagliflozin and empagliflozin significantly decreased incremental glucose AUCs, with no significant difference between treatment groups ( ...

Sotagliflozin and Kidney Outcomes, Kidney Function, and Albu...

In this exploratory analysis using the complete laboratory dataset, sotagliflozin reduced the risk of kidney and cardiorenal composite end points in patients ...

New Secondary Analysis of Phase 3 Data Demonstrates that ...

(Nasdaq: LXRX) today announced that a post-hoc analysis of Phase 3 data from the SCORED clinical trial demonstrated that INPEFA® (sotagliflozin) ...

New Analysis of Phase 3 Data Demonstrating Renal Protective ...

Results showed a placebo-adjusted acute decline in eGFR of -2.59 ml/min/1.73m2/year across 10,574 participants. Notably, sotagliflozin ...

New Secondary Analysis of Phase 3 Data Demonstrates that

(Nasdaq: LXRX) today announced that a post-hoc analysis of Phase 3 data from the SCORED clinical trial demonstrated that INPEFA® (sotagliflozin) ...

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That Inpefa ...

(Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data showing that INPEFA® (sotagliflozin), a dual oral inhibitor of SGLT2 and ...

Benefits of SGLT1/2 Inhibition with Sotagliflozin Across Baseline ...

eGFR ≥60 analysis was post hoc. • However, both types of analyses were consistent in terms of demonstrating benefits. Bhatt DL. AHA 2021, virtual. Page 24 ...

New Data on Renal Protective Benefits of Sotagliflozin Will be ...

In a post hoc analysis of the SCORED trial, investigators observed positive renal protection with sotagliflozin across a spectrum of ...

Effects of Sotagliflozin on Health Status in Patients With Worsening ...

In this prespecified analysis from the SOLOIST-WHF trial, the benefits of sotagliflozin on reducing clinical events were consistent across ...

Effects of Sotagliflozin on Health Status in Patients With Worsening ...

Sotagliflozin vs placebo reduced the risk of the primary endpoint consistently across KCCQ-12 tertiles (Ptrend = 0.54). Sotagliflozin-treated patients vs those ...

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials

SCORED is also the first trial to illustrate the benefits of the class across the full range of albuminuria. Moreover, the endpoint of stroke ...

Time to clinical benefit with sotagliflozin in patients with type 2 ...

In conclusion, among patients in SCORED, sotagliflozin reduced HF outcomes with significant benefit seen early and sustained throughout the ...

A Dual SGLT2 and SGLT1 Inhibitor—in the Treatment of Heart Failure

Conclusions: Dual SGLT1 and SGLT2 inhibition with sotagliflozin is efficacious in reducing myocardial infarction (MI), stroke, and HF ...

Sotagliflozin - an overview | ScienceDirect Topics

However, as in other SGLT2 inhibitors, the metabolic benefits of the drug do not seem to depend exclusively on its activity in controlling blood glucose levels.

Time to Benefit With Sotagliflozin in Patients With Worsening Heart ...

In the present analysis, we calculated the HRs and 95% CIs for each of these outcomes with sotagliflozin vs placebo by time and determined the ...

New Analyses of Sotagliflozin Showing Time to Clinical Benefit ...

The analysis showed a statistically significant reduction in the risk for the primary outcome on Day 27, or time to clinical benefit of 27 days, in patients ...

Lexicon's Sotagliflozin Demonstrates Benefits in Heart

“In this new analysis of pooled clinical data from the SOLOIST and SCORED trials, sotagliflozin consistently reduced total cardiovascular deaths ...